Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.

ABSTRACT:

Importance

The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown.

Objective

To assess subsequent outcomes of eyes with DME persisting for 24 weeks after initiating treatment with 0.5 mg of ranibizumab.

Design, setting, and participants

We performed post hoc, exploratory analyses of a randomized clinical trial from March 20, 2007, through January 29, 2014, from 117 of 296 eyes (39.5%) randomly assigned to receive ranibizumab with persistent DME (central subfield thickness ≥250 μm on time domain optical coherence tomography) through the 24-week visit.

Interventions

Four monthly intravitreous injections of ranibizumab and then as needed per protocol.

SUBMITTER: Bressler SB 

PROVIDER: S-EPMC4786449 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature